甘精胰岛素/利司那肽复方制剂在2型糖尿病中的临床应用

Insulin Glargine/lixisenatide in Type 2 Diabetes:a Profile of its Use

甘精胰岛素/利司那肽皮下注射剂[Suliqua■100/33和100/50(欧洲上市);Soliqua■100/33(美国上市)]是一种剂量可调、固定比例的长效基础胰岛素类似物+胰高糖素样肽-1受体激动剂复方制剂,它被批准用于治疗成年2型糖尿病血糖控制不佳的患者。Ⅲ期临床试验表明,在未使用过胰岛素的2型糖尿病患者中,甘精胰岛素/利司那肽复方制剂(每日一次皮下注射)对于血糖控制的效果优于甘精胰岛素或利司那肽(+二甲双胍);而在使用过胰岛素2型糖尿病患者中,其血糖控制效果也优于甘精胰岛素(±二甲双胍)。与甘精胰岛素相比,该复方制剂可改善体重,且不增加低血糖风险。且该复方制剂耐受性良好、使用便捷。因此,当成人2型糖尿病单用二甲双胍或联用其他口服降糖药,或口服降糖药联用基础胰岛素均不能很好地控制血糖时,该复方制剂为临床提供了另一宝贵的降糖选择。本文对2019年发表在Drugs&Therapy Perspectives杂志上的文章“甘精胰岛素/利司那肽复方制剂在2型糖尿病中的临床应用”进行中文摘译。

Subcutaneous insulin glargine/lixisenatide[Suliqua■100/33 and 100/50(EU);Soliqua■100/33(USA)]is a titratable,fixed-ratio combination of a long-acting basal insulin analogue+a glucagon-like peptide-1 receptor agonist(GLP-1 RA)approved to treat inadequately controlled type 2 diabetes(T2DM)in adults.Once-daily insulin largine/lixisenatide provided glycaemic control better than that of insulin glargine or lixisenatide in insulin-naive patients(when added to metformin)and better than that of insulin glargine in insulin-experienced patients(when used±metformin)in phase 3 trials in adults with inadequately controlled T2DM.It is,therefore,a valuable option for improving glycaemic control in adults with T2DM when this has not been provided by metformin alone or metformin+another oral antihyperglycaemic agent or+basal insulin.